84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]杜彪,韓星敏,劉艷,等.超級(jí)骨顯像影像學(xué)特征診斷惡性腫瘤骨轉(zhuǎn)移和代謝性骨病的應(yīng)用價(jià)值[J].中醫(yī)正骨,2022,34(07):46-47.
點(diǎn)擊復(fù)制

超級(jí)骨顯像影像學(xué)特征診斷惡性腫瘤骨轉(zhuǎn)移和代謝性骨病的應(yīng)用價(jià)值()
分享到:

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第34卷
期數(shù):
2022年07期
頁(yè)碼:
46-47
欄目:
影像診斷
出版日期:
2022-07-20

文章信息/Info

作者:
杜彪韓星敏劉艷謝新立王旭劉保平
(鄭州大學(xué)第一附屬醫(yī)院,河南 鄭州 450052)
關(guān)鍵詞:
腫瘤轉(zhuǎn)移 骨疾病代謝性 放射性核素顯像 影像學(xué)特征
摘要:
目的:探討超級(jí)骨顯像影像學(xué)特征診斷惡性腫瘤骨轉(zhuǎn)移和代謝性骨病的應(yīng)用價(jià)值。方法:納入299例全身骨顯像檢查表現(xiàn)為超級(jí)骨顯像患者的病例資料。男223例,女76例。年齡22~86歲,中位數(shù)67歲。臨床診斷確診惡性腫瘤骨轉(zhuǎn)移246例、代謝性骨病53例。由3名高年資核醫(yī)學(xué)醫(yī)師分析患者的超級(jí)骨顯像圖像,根據(jù)惡性腫瘤骨轉(zhuǎn)移和代謝性骨病的超級(jí)骨顯像影像學(xué)特征判斷患者疾病,統(tǒng)計(jì)診斷結(jié)果,與臨床診斷確診結(jié)果比較,分別計(jì)算惡性腫瘤骨轉(zhuǎn)移和代謝性骨病的超級(jí)骨顯像影像學(xué)特征診斷相應(yīng)疾病的敏感度、特異度、陽(yáng)性預(yù)測(cè)值和陰性預(yù)測(cè)值。結(jié)果:超級(jí)骨顯像影像學(xué)特征診斷惡性腫瘤骨轉(zhuǎn)移的敏感度為91.87%、特異度為85.96%、陽(yáng)性預(yù)測(cè)值為96.58%、陰性預(yù)測(cè)值為71.01%,超級(jí)骨顯像影像學(xué)特征診斷代謝性骨病的敏感度為84.91%、特異度為92.00%、陽(yáng)性預(yù)測(cè)值為69.23%、陰性預(yù)測(cè)值為96.64%。結(jié)論:超級(jí)骨顯像影像學(xué)特征診斷惡性腫瘤骨轉(zhuǎn)移和代謝性骨病具有一定的應(yīng)用價(jià)值。

參考文獻(xiàn)/References:

[1] 程艷,羅麗萍,胡珊,等.骨顯像劑異常濃聚程度及前列腺癌骨轉(zhuǎn)移預(yù)測(cè)模型的單中心研究[J].中華腫瘤雜志,2020,42(10):876-881.
[2] PETERSEN L J,MORTENSEN J C,BERTELSEN H,et al.Computer-assisted interpretation of planar whole-body bone scintigraphy in patients with newly diagnosed prostate cancer[J].Nucl Med Commun,2015,36(7):679-685.
[3] BIELICKAITE J,ZADEIKAITE R,JURKIENE N,et al.Comparison of serum prostate specific antigen levels and bone scintigraphy in patients with prostate carcinoma[J].Medicina(Kaunas),2003,39(9):867-871.
[4] BORO H,GOYAL A,NAIK S S,et al.Primary Sj?gren's syndrome manifesting as sclerotic metabolic bone disease[J/OL].BMJ Case Rep,2021,14(1)[2021-02-24].https://pubmed.ncbi.nlm.nih.gov/33431459/.
[5] KRISHNAPPA B,JADHAV S R,LILA A R,et al.Tumour-induced osteomalacia due to an intra-abdominal mesenchymal tumour[J/OL].BMJ Case Rep,2019,12(12)[2021-02-24].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904179/.
[6] 曾令鵬,羅侃瑩,張慶,等.58例超級(jí)骨顯像分析[J].中國(guó)臨床醫(yī)學(xué)影像雜志,2020,31(6):446-449.
[7] 曾令鵬,張慶,關(guān)晏星,等.POEMS綜合征骨顯像表現(xiàn)為超級(jí)骨顯像1例[J].中國(guó)臨床醫(yī)學(xué)影像雜志,2020,31(1):74-75.
[8] 任靜蕓,李燕,羅亞平.超級(jí)骨顯像的鑒別診斷一例[J].中華核醫(yī)學(xué)與分子影像雜志,2019,39(1):39-40.
[9] KULKARNI M,SONI A,SHETKAR S,et al.Coexistent superscan and Lincoln sign on bone scintigraphy[J].Clin Nucl Med,2017,42(8):630-632.
[10] 安銳,黃鋼.核醫(yī)學(xué)[M].3版.北京:人民衛(wèi)生出版社,2015:241-247.
[11] 黃建敏,潘莉萍,劉曉梅,等.骨掃描中的超級(jí)骨顯像[J].中國(guó)臨床醫(yī)學(xué)影像雜志,2009,20(9):711-713.
[12] BUCKLEY O,O'KEEFFE S,GEOGHEGAN T,et al.99mTc bone scintigraphy superscans:a review[J].Nucl Med Commun,2007,28(7):521-527.
[13] HARSHMAN L K,LATIFI H R,GRIFFETH L K.Visualization of discrete sacral foramina as an ancillary sign of superscan[J].Clin Nucl Med,2011,36(1):21-24.
[14] PACCOU J,PFLIMLIN A,GLOWACKI F,et al.A challen-ging case of tumor-induced osteomalacia[J].Am J Med,2021,134(1):e60-e61.
[15] LIN C Y,CHEN Y W,CHANG C C,et al.Bone metastasis versus bone marrow metastasis?Integration of diagnosis by(18)F-fluorodeoxyglucose positron emission/computed tomography in advanced malignancy with super bone scan:two case reports and literature review[J].Kaohsiung J Med Sci,2013,29(4):229-233.
[16] 王立興,朱吉高,劉娟.腎性骨病的影像診斷分析[J].廣西中醫(yī)學(xué)院學(xué)報(bào),2010,13(1):34-35.
[17] LACOMBE J M,ROPER R J.Skeletal dynamics of down syndrome:a developing perspective[J/OL].Bone,2020,133[2021-02-24].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044033/.

相似文獻(xiàn)/References:

[1]朱麗英,胡春艷,贠春燕,等.血清Ⅰ型前膠原氨基端前肽與Ⅰ型膠原羧基端肽β特殊序列在惡性腫瘤骨轉(zhuǎn)移診斷和病情評(píng)估及療效評(píng)價(jià)中的應(yīng)用價(jià)值[J].中醫(yī)正骨,2018,30(06):30.
 ZHU Liying,HU Chunyan,YUN Chunyan,et al.Applied values of serum N-terminal propeptide of typeⅠprecollagen and β cross-linked C-telopeptide of typeⅠcollagen in diagnosis,severity assessment and therapeutic efficacy evaluation of bone metastasis of malignant tumors[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(07):30.

備注/Memo

備注/Memo:
通訊作者:劉保平 E-mail:[email protected]
更新日期/Last Update: 1900-01-01